SI9200138A - Pharmaceutical product for the treatment of states of acitation and nerve dysfunctions - Google Patents
Pharmaceutical product for the treatment of states of acitation and nerve dysfunctions Download PDFInfo
- Publication number
- SI9200138A SI9200138A SI19929200138A SI9200138A SI9200138A SI 9200138 A SI9200138 A SI 9200138A SI 19929200138 A SI19929200138 A SI 19929200138A SI 9200138 A SI9200138 A SI 9200138A SI 9200138 A SI9200138 A SI 9200138A
- Authority
- SI
- Slovenia
- Prior art keywords
- corydalis
- eschscholtzia
- extract
- extracts
- medicament
- Prior art date
Links
- 230000004064 dysfunction Effects 0.000 title claims description 9
- 210000005036 nerve Anatomy 0.000 title claims description 7
- 239000000825 pharmaceutical preparation Substances 0.000 title description 2
- 229940127557 pharmaceutical product Drugs 0.000 title 1
- 239000000284 extract Substances 0.000 claims description 111
- 241000218176 Corydalis Species 0.000 claims description 57
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 49
- 239000003814 drug Substances 0.000 claims description 49
- 229940079593 drug Drugs 0.000 claims description 30
- 229960003638 dopamine Drugs 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 16
- 230000001476 alcoholic effect Effects 0.000 claims description 15
- 230000004060 metabolic process Effects 0.000 claims description 15
- 238000000605 extraction Methods 0.000 claims description 13
- 239000012675 alcoholic extract Substances 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 4
- 208000012639 Balance disease Diseases 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000008030 elimination Effects 0.000 claims description 3
- 238000003379 elimination reaction Methods 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008298 dragée Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000037007 arousal Effects 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 46
- 230000000694 effects Effects 0.000 description 38
- 102000010909 Monoamine Oxidase Human genes 0.000 description 29
- 108010062431 Monoamine oxidase Proteins 0.000 description 29
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 20
- 102000004190 Enzymes Human genes 0.000 description 19
- 108090000790 Enzymes Proteins 0.000 description 19
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 18
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 18
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 15
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 14
- 102000003425 Tyrosinase Human genes 0.000 description 13
- 108060008724 Tyrosinase Proteins 0.000 description 13
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 11
- WTDRDQBEARUVNC-UHFFFAOYSA-N dopa Chemical compound OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 238000011835 investigation Methods 0.000 description 10
- 238000007254 oxidation reaction Methods 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 239000008363 phosphate buffer Substances 0.000 description 9
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 8
- 235000010323 ascorbic acid Nutrition 0.000 description 8
- 239000011668 ascorbic acid Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000003647 oxidation Effects 0.000 description 8
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 8
- 239000010949 copper Substances 0.000 description 7
- 230000037323 metabolic rate Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 229960005070 ascorbic acid Drugs 0.000 description 6
- 150000003943 catecholamines Chemical class 0.000 description 6
- 150000002009 diols Chemical class 0.000 description 6
- 238000006911 enzymatic reaction Methods 0.000 description 6
- 230000033444 hydroxylation Effects 0.000 description 6
- 238000005805 hydroxylation reaction Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 5
- 102000004316 Oxidoreductases Human genes 0.000 description 5
- 108090000854 Oxidoreductases Proteins 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 229960004502 levodopa Drugs 0.000 description 4
- 229960002748 norepinephrine Drugs 0.000 description 4
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 4
- 230000036284 oxygen consumption Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 229940098465 tincture Drugs 0.000 description 4
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 206010029216 Nervousness Diseases 0.000 description 3
- 208000027089 Parkinsonian disease Diseases 0.000 description 3
- 206010034010 Parkinsonism Diseases 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- WOAHJDHKFWSLKE-UHFFFAOYSA-N 1,2-benzoquinone Chemical compound O=C1C=CC=CC1=O WOAHJDHKFWSLKE-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 229940072107 ascorbate Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 108040001319 catechol oxidase activity proteins Proteins 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940114166 dl dopa Drugs 0.000 description 2
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229940050411 fumarate Drugs 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 230000008557 oxygen metabolism Effects 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 239000008024 pharmaceutical diluent Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229960003732 tyramine Drugs 0.000 description 2
- XKZQKPRCPNGNFR-UHFFFAOYSA-N 2-(3-hydroxyphenyl)phenol Chemical compound OC1=CC=CC(C=2C(=CC=CC=2)O)=C1 XKZQKPRCPNGNFR-UHFFFAOYSA-N 0.000 description 1
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-Dihydroxybenzaldehyde Natural products OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 1
- ATTTYDOGGQCDDK-UHFFFAOYSA-N C1=CC2=CC(=O)C(=O)NC2=C2C=CN=C21 Chemical compound C1=CC2=CC(=O)C(=O)NC2=C2C=CN=C21 ATTTYDOGGQCDDK-UHFFFAOYSA-N 0.000 description 1
- 241001576541 Corydalis cava Species 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- 102000004020 Oxygenases Human genes 0.000 description 1
- 108090000417 Oxygenases Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- PUTCXBJUWNRWJH-UHFFFAOYSA-N cyclohexa-3,5-diene-1,1,2-triol Chemical compound OC1C=CC=CC1(O)O PUTCXBJUWNRWJH-UHFFFAOYSA-N 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 108010051081 dopachrome isomerase Proteins 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- BTXNYTINYBABQR-UHFFFAOYSA-N hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 description 1
- 229940005608 hypericin Drugs 0.000 description 1
- PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000006395 oxidase reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 description 1
- 230000035485 pulse pressure Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/50—Fumariaceae (Fumitory family), e.g. bleeding heart
- A61K36/505—Corydalis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4122706A DE4122706C1 (enExample) | 1991-07-09 | 1991-07-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI9200138A true SI9200138A (en) | 1993-03-31 |
Family
ID=6435763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI19929200138A SI9200138A (en) | 1991-07-09 | 1992-07-08 | Pharmaceutical product for the treatment of states of acitation and nerve dysfunctions |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US5308619A (enExample) |
| EP (1) | EP0535317B1 (enExample) |
| JP (1) | JPH085796B2 (enExample) |
| KR (1) | KR100225010B1 (enExample) |
| AT (1) | ATE139446T1 (enExample) |
| AU (1) | AU652262B2 (enExample) |
| CA (1) | CA2072950A1 (enExample) |
| CZ (1) | CZ279915B6 (enExample) |
| DE (2) | DE4122706C1 (enExample) |
| DK (1) | DK0535317T3 (enExample) |
| EE (1) | EE03169B1 (enExample) |
| EG (1) | EG20140A (enExample) |
| ES (1) | ES2088053T3 (enExample) |
| GR (1) | GR3020289T3 (enExample) |
| HU (1) | HUT61668A (enExample) |
| IE (1) | IE74691B1 (enExample) |
| IL (1) | IL102410A (enExample) |
| MD (1) | MD1139G2 (enExample) |
| MX (1) | MX9204011A (enExample) |
| PT (1) | PT100668B (enExample) |
| RU (1) | RU2072859C1 (enExample) |
| SI (1) | SI9200138A (enExample) |
| SK (1) | SK279531B6 (enExample) |
| UA (1) | UA26971C2 (enExample) |
| YU (1) | YU48554B (enExample) |
| ZA (1) | ZA925059B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5460819A (en) * | 1991-12-13 | 1995-10-24 | Children's Medical Center Corporation | Method for treating PQQ-responsive heavy metal toxicity |
| FR2743721B1 (fr) * | 1996-01-19 | 1998-04-03 | Innothera Lab Sa | Association mineralo-phytotherapique sous forme galenique unitaire de comprimes |
| PT1066042E (pt) * | 1998-03-26 | 2006-12-29 | Phytopharm Plc | Saponinas esteroides para o tratamento de doença de alzheimer |
| NZ514253A (en) | 1999-03-11 | 2003-06-30 | Zeachem Inc | Process for producing ethanol |
| US7074603B2 (en) * | 1999-03-11 | 2006-07-11 | Zeachem, Inc. | Process for producing ethanol from corn dry milling |
| US6521634B2 (en) | 2001-03-28 | 2003-02-18 | The Hong Kong University Of Science & Technology | Uses of dl-THP |
| KR20030063735A (ko) * | 2002-01-23 | 2003-07-31 | 주식회사 석산터메디칼 | 신경성 질환 예방 및 치료를 위한 약제학적 조성물 및,실험용 동물에 신경성 질환을 일으키는 방법 |
| US7341745B2 (en) * | 2003-02-07 | 2008-03-11 | Arizona Health Consulting, Llc | Method for decreasing nicotine and other substance use in humans |
| NZ586246A (en) * | 2004-01-29 | 2013-03-28 | Zeachem Inc | Recovery of organic acids from a fermentation broth |
| FR2878163B1 (fr) * | 2004-11-25 | 2007-04-27 | R & D Pharma | Nouvelles compositions pharmaceutiques a visee phytotherapeutique |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR961M (enExample) * | 1961-03-03 | 1961-11-27 | ||
| DE1467868A1 (de) * | 1964-10-20 | 1969-01-30 | Dainippon Pharmaceutical Co | Verfahren zur Herstellung eines gegen Geschwuere des Verdauungstraktes wirksamen Medikamentes |
| JPS60181023A (ja) * | 1984-02-28 | 1985-09-14 | Nitto Electric Ind Co Ltd | 漢方局所麻酔性組成物 |
-
1991
- 1991-07-09 DE DE4122706A patent/DE4122706C1/de not_active Expired - Fee Related
-
1992
- 1992-07-02 AU AU19370/92A patent/AU652262B2/en not_active Ceased
- 1992-07-02 CA CA002072950A patent/CA2072950A1/en not_active Abandoned
- 1992-07-03 IL IL102410A patent/IL102410A/en not_active IP Right Cessation
- 1992-07-06 YU YU67492A patent/YU48554B/sh unknown
- 1992-07-07 US US07/909,675 patent/US5308619A/en not_active Expired - Fee Related
- 1992-07-07 ZA ZA925059A patent/ZA925059B/xx unknown
- 1992-07-08 SI SI19929200138A patent/SI9200138A/sl unknown
- 1992-07-08 EG EG37092A patent/EG20140A/xx active
- 1992-07-08 KR KR1019920012112A patent/KR100225010B1/ko not_active Expired - Fee Related
- 1992-07-08 PT PT100668A patent/PT100668B/pt not_active IP Right Cessation
- 1992-07-08 RU SU925052267A patent/RU2072859C1/ru active
- 1992-07-08 IE IE922226A patent/IE74691B1/en not_active IP Right Cessation
- 1992-07-08 MX MX9204011A patent/MX9204011A/es not_active IP Right Cessation
- 1992-07-09 JP JP4182626A patent/JPH085796B2/ja not_active Expired - Lifetime
- 1992-07-09 CZ CS922143A patent/CZ279915B6/cs not_active IP Right Cessation
- 1992-07-09 ES ES92111709T patent/ES2088053T3/es not_active Expired - Lifetime
- 1992-07-09 SK SK2143-92A patent/SK279531B6/sk unknown
- 1992-07-09 HU HU9202274A patent/HUT61668A/hu unknown
- 1992-07-09 AT AT92111709T patent/ATE139446T1/de not_active IP Right Cessation
- 1992-07-09 DK DK92111709.9T patent/DK0535317T3/da active
- 1992-07-09 EP EP92111709A patent/EP0535317B1/de not_active Expired - Lifetime
- 1992-07-09 DE DE59206608T patent/DE59206608D1/de not_active Expired - Fee Related
-
1993
- 1993-03-12 UA UA93002403A patent/UA26971C2/uk unknown
-
1994
- 1994-08-09 EE EE9400046A patent/EE03169B1/xx unknown
- 1994-12-30 MD MD95-0171A patent/MD1139G2/ro unknown
-
1996
- 1996-06-20 GR GR960401185T patent/GR3020289T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Latha et al. | Preventive effects of Cassia auriculata L. flowers on brain lipid peroxidation in rats treated with streptozotocin | |
| Shih et al. | Antihyperglycaemic and anti‐oxidant properties of Anoectochilus formosanus in diabetic rats | |
| Ezekwesili et al. | Anti-diabetic activity of aqueous extracts of Vitex doniana leaves and Cinchona calisaya bark in alloxan–induced diabetic rats | |
| SI9200138A (en) | Pharmaceutical product for the treatment of states of acitation and nerve dysfunctions | |
| Domekouo et al. | Evaluation of the antidiabetic and antioxidant properties of Morinda lucida stem bark extract in streptozotocin intoxicated rats. | |
| Kumar et al. | Antihyperglycaemic and antiperoxidative effect of Helicteres isora L. bark extracts in streptozotocin-induced diabetic rats | |
| US20060034763A1 (en) | Therapeutic use of resveratrol for hyperglycemia | |
| Kade et al. | Aqueous extracts of Sphagneticola trilobata attenuates streptozotocin-induced hyperglycaemia in rat models by modulating oxidative stress parameters | |
| Adeneye et al. | Glucose utilization and anti-oxidative mechanisms of the aqueous hunteria umbellata seed extract in alloxan-induced diabetic rats | |
| Nkanu et al. | In vivo. hypolipidemic and hypoglycemic effects of aqueous extract of Spondias mombin leaves and detoxification of reactive oxygen species in alloxan-induced diabetic rats | |
| Mughal et al. | Protective effect of Helianthus annuus seeds extract against CCl4-induced hepatocellular damage | |
| Esan et al. | The Effects of okra (Abelmoschus esculentus (L) M oench) fruit extracts on diabetes markers in streptozotocin-induced diabetic rats. Arch | |
| Kopin et al. | MPTP-induced parkinsonian syndromes in humans and animals | |
| James et al. | Chemical Composition And Anti-Diabetic Effect Of Jatropha Curcas Leaves Extract On Alloxan-Induced Diabetic Albino Rats | |
| Babby et al. | Effect of tannic acid on lipid peroxidation and antioxidants status in streptozotocin induced diabetic rats | |
| Chidi et al. | Anti-hyperglycemic and anti-oxidant activities of methanol extract of Gongronema latifolium | |
| Zeid et al. | Augmentation of Insulin Secretion Induced by Rhizophora Mucronata and Avicennia Marina Extracts in Streptozotocin-Induced Diabetic Rats | |
| Sanilkumar et al. | Evaluation of in-vivo antioxidant activity of methanolic extract of Triumfetta rotundifolia (Linn.) on streptozotocin induced oxidative stress in Wistar rats | |
| Ibraheem | A Comparative Study of the Antiulcerogenic Effect of Hydroethanol and Fractionated Extracts of Verbena hastata Leaves on Indomethacine Induced Gastric Ulcer in Albino Rats | |
| Pingale et al. | Syzygium cumini Protects Diabetic Wistar Rats Against Rosiglitazone-Induced Cardiotoxicity and Hepatotoxicity | |
| LT3355B (en) | Pharmaceutical and its use for the treatment of states of agitation and nerve dysfunctions | |
| Srivastava et al. | Hypoglycemic effect of polyherbal formulations in alloxan induced diabetic mice | |
| Konda et al. | AMELIORATIVE EFFECT OF BACOPA MONNIERI ON CARDIAC OXIDATIVE STRESS IN STZ INDUCED DIABETIC WISTER ALBINO RAT. | |
| Makinwa et al. | Effects of NaCl and Lime water on the Hypoglycemic and Antioxidant activities of Ocimum gratissimum in Alloxan-induced Diabetic rats. | |
| Christian et al. | In vivo antidiabetic effect of a combination of ethanol extract of Ficus capensis and Cnidoscolus aconitifolius leaves in alloxan-induced diabetic rats |